We present a single-centre experience of the use of Obinutuzumab in treatment-resistant or recurrent membranous nephropathy, with 5 cases reported: 3 cases of PLA2R-associated membranous nephropathy, 1 case of secondary membranous nephropathy (sarcoidosis), and 1 case of recurrent primary membranous nephropathy in a renal allograft. The gene discussed is PLA2R1; the disease is membranous glomerulonephritis.